articleThe LancetApr 1, 2004Closed access

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

FVFrank van LethPPPraphan PhanuphakKRKiat RuxrungthamEBEzio BaraldiSMSheila Miller

Academic Medical Center · University of Amsterdam · +23 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

683
total citations
FWCI
37.42
Percentile
100%
References
35
Citations per year

Authors

29

Topics & keywords

Topics
Keywords
  • Nevirapine
  • Efavirenz
  • Lamivudine
  • Stavudine
  • Medicine
  • Reverse-transcriptase inhibitor
  • Internal medicine
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.